

RECEIVED

MAY 10 2001

 Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO:	TECH CENTER 1600/2900
	P-TB 4567	09/765,696
	APPLICANT: Daniel S. Sem	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: January 19, 2001	GROUP: 1627

U.S. PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
<i>MS</i>	4,863,876	9/5/89	Richard C. Hevey	436	537	
	5,422,281	6/6/95	Harris et al.	436	501	
	5,585,277	12/17/96	Bowie & Pakula	436	518	
	5,661,019	8/26/97	Oh et al.	435	174	
	5,527,686	6/18/96	Fitzpatrick et al.	435	7.9	
	5,658,739	8/19/97	Virgil L. Woods Jr.	435	7.1	
	5,679,582	10/21/97	Bowie et al.	436	518	
	5,693,515	12/2/97	Clark et al.	435	184	
	5,698,401	12/16/97	Fesik et al.	435	7.1	
	5,710,009	1/20/98	Fitzpatrick et al.	435	7.9	
	5,710,129	1/20/98	Lynch et al.	514	018	
	5,717,092	2/10/98	Armistead et al.	544	129	
	5,723,490	3/3/98	Tung	514	478	
	5,830,462	11/3/98	Crabtree et al.	424	093.21	
<i>MS</i>	5,804,390	9/8/98	Fesik & Hajduk	435	7.1	

FOREIGN PATENT DOCUMENTS


EXAM. INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
<i>MS</i>	WO/89 04315	18/5/89	PTW WIPO			

EXAMINER <i>M</i>	DATE CONSIDERED <i>11/18/01</i>
----------------------	------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

MAY 10 2001

 Form PTO 1449 US Department of Commerce Patent and Trademark Office MAY 07 2001 PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO:	TECH CENTER 1600/2900
		P-TB 4567	SERIAL NO. 09/765,696
		APPLICANT: Daniel S. Sem	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: January 19, 2001	GROUP: 1627

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

<i>MS</i>	Appelt et al., "Design of enzyme inhibitors using iterative protein crystallographic analysis," <u>J. Med. Chem.</u> 34:1925-1934 (1991)
	Baldock et al., "A mechanism of drug action revealed by structural studies of enoyl reductase," <u>Science</u> 274:2107-2110 (1996)
	Bayomi et al., "Probing the thymidylate synthase active site with bisubstrate analog inhibitors," <u>Nucleosides & Nucleotides</u> 7:103-115 (1988)
	Bellamacina, Cornelia R., "The nicotinamide dinucleotide binding motif: a comparison of nucleotide binding proteins," <u>FASEB J.</u> 10:1257-1269 (1996)
	Bemis and Murcko, "The Properties of Known Drugs. 1. Molecular Frameworks," <u>J. Med. Chem.</u> , 39:2887-2893 (1996)
	Bull et al., "Mechanism-based inhibition of human steroid 5 α -reductase by finasteride: enzyme-catalyzed formation of NADP-Dihydrofinasteride, a protein bisubstrate analog inhibitor," <u>J. Am. Chem. Soc.</u> 118:2359-2365 (1996)
	Burke, Terrance R., "Protein-tyrosine kinase inhibitors," <u>Drugs of the Future</u> 17:119-131 (1992)
	Chen et al., "Biased combinatorial libraries: novel ligands for the SH3 domain of phosphatidylinositol 3-kinase," <u>J. Am. Chem. Soc.</u> 115:12591-12592 (1993)
	Combs et al., "Protein structure-based combinatorial chemistry: discovery of non-peptide binding elements to Src SH3 domain," <u>J. Am. Soc.</u> 118:287-288 (1996)
	Cohen et al., "Modular binding domains in signal transduction proteins," <u>Cell</u> , 80:237-248 (1995)
<i>MS</i>	Constantine et al., "Characterization of NADP $^+$ Binding to Perdeuterated MurB: Backbone Atom NMR Assignments and Chemical-shift Changes," <u>J. Mol. Biol.</u> , 267:1223-1246 (1997)

EXAMINER <i>Ain</i>	DATE CONSIDERED <i>11/18/01</i>
-------------------------------	---

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

MAY 10 2001

TECH CENTER 1600
SERIAL NO.
09/765,698

		ATTY DOCKET NO:	
		P-TB 4567	
		APPLICANT:	Daniel S. Sem
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE:	January 19, 2001
		GROUP:	1627

<i>M</i>	Dalgarno et al., "SH3 domains and drug design: ligands, structure, and biological function," <u>Biopolymers</u> 43:383-400 (1998)
	Davis et al., "Alterations in chemical shifts and exchange broadening upon peptide boronic acid inhibitor binding to α -lytic protease," <u>J. Biomolecular NMR</u> 10:21-27 (1997)
	Davey and Fenna, "2.3 Å resolution x-ray crystal structure of the bisubstrate analogue inhibitor salicylhydroxamic acid bound to human myeloperoxidase: a model for a prereaction complex with hydrogen peroxide," <u>Biochem.</u> 35:10967-10973 (1996)
	Farmer et al., "Localizing the NADP ⁺ binding site on the MurB enzyme by NMR," <u>Nat. Structural Biol.</u> , 3:995-997 (1996)
	Fejzo et al., "Dynamic NMR studies of ligand-receptor interactions: Design and analysis of a rapidly exchanging complex of RKBP-12/FK506 with a 24 kDa calcineurin fragment," <u>Protein Sci.</u> , 5:1917-1921 (1996)
	Fejzo et al., "The SHAPES Strategy: An NMR Based Approach for Lead Generation in Drug Discovery," Abstract MIIA-4 International Conference on Magnetic Resonance in Biological Systems Meeting, Tokyo (1998)
	Feng et al., "Specific interactions outside the proline-rich core of two classes of Src homology 3 ligands," <u>Proc. Natl. Acad. Sci. USA</u> , 92:12408-12415 (1995)
	Feng et al., "Molecular basis for the binding of SH3 ligands with non-peptide elements identified by combinatorial synthesis," <u>Chem. & Biol.</u> 3:661-670 (1996)
	Feng and Schreiber, "Enantiomeric binding elements interacting at the same site of an SH3 protein receptor," <u>J. Am Chem. Soc.</u> 119:10873-10874 (1997)
	Gray et al., "Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors," <u>Science</u> 281:533-538 (1998)
<i>M</i>	Hajduk et al., "Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR," <u>J. Am. Chem. Soc.</u> 119:5818-5827 (1997)

EXAMINER	DATE CONSIDERED
	11/18/01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.